百家乐怎么玩-澳门百家乐官网娱乐城网址_网上百家乐是不是真的_全讯网888 (中国)·官方网站

Recent advances in the synthesis, stability, and activation of platinum(IV) anticancer prodrugs
20210518_1.jpeg

Published on Angewandte Chemie (18 May 2021)

 

Author(s): Zoufeng Xu, Zhigang Wang, Zhiqin Deng, Guangyu Zhu*

 

Abstract

Platinum-based anticancer drugs have been widely applied in clinical settings for more than 40 years. The remarkable breakthroughs that have come from the use of these complexes in cancer therapy have stimulated a continual search for new platinum anticancer drugs. The most promising result of these efforts is a prodrug strategy based on the use of platinum(IV) versions of the traditional platinum(II) anticancer drugs. Hence, the design of synthetic methods for platinum(IV) prodrugs and an understanding of their hydrolytic stability and intracellular activation processes are critical for the development of platinum(IV) prodrugs for cancer therapy. In this review, we summarize recent progress in this field from a comprehensive viewpoint, with an emphasis first on the oxidation processes in chemical environments where platinum(II) compounds are converted to their platinum(IV) species, followed by the reduction processes in biological environments where platinum(IV) species are converted back to platinum(II) forms. First, recent approaches that use new oxidizing reagents to synthesize platinum(IV) prodrugs are summarized, and the oxidation mechanisms and outer-sphere functionalization of platinum(IV) prodrugs are examined. Second, the hydrolysis of platinum(IV) complexes, which has sometimes been underexplored, is discussed, and the factors associated with the hydrolytic stability of platinum(IV) complexes are reviewed. Last, we focus on the reduction of platinum(IV) prodrugs, from the perspectives of reduction potential, rate of reduction, reducing agents, and reduction products. The need for new strategies to achieve controllable intracellular reduction of platinum(IV) prodrugs is emphasized. This review aims to help researchers to improve their understanding of platinum(IV) anticancer prodrugs and hopefully to generate new ideas, strategies, and applications in the area of metal-based drugs.

 

20210518_2.jpeg


Read more: https://doi.org/10.1016/j.ccr.2021.213991

 

 

background
 
 
 
 
 
 
 
 
百家乐款| 大发888信誉| 专业百家乐分析| 合乐8百家乐娱乐城| 澳门百家乐官网打缆| 百家乐998| 网上百家乐官网能作弊吗| 百利宫百家乐现金网| 百家乐官网视频大厅| 百家乐赌场赌场平台| 真钱赌博| 皇室百家乐的玩法技巧和规则| 德州扑克的技巧| 淘宝博百家乐官网的玩法技巧和规则| 老k棋牌游戏大厅| 百家乐投注科学公式| 百家乐官网游戏技巧| 威尼斯人娱乐场官网48008| 澳门百家乐官网群代理| 湖南省| 大发888 bet娱乐场下载| 百家乐路单规则| 百家乐官网赌法博彩正网| 顶级赌场连环夺宝下注有什么窍门| 娱乐城百家乐打不开| 百家乐官网真人游戏网| 大发888客服qq号| 百家乐庄闲机率分析| 百家乐官网游戏全讯网2| 大世界娱乐| 百家乐看| 百家乐三路秘诀| 澳门百家乐官网海洋阿强| 钻石国际娱乐| 什么是百家乐平注法| 总格24画的名字好吗| 上市百家乐评论| 大发888dafa888| 百家乐技巧下载| 澳门百家乐加盟| 巴黎人百家乐官网的玩法技巧和规则|